APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glial Cell Line Derived Neurotrophic Factor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast 2026-2032

19 December 2025193 pages

Choose your research edition.

Industry ResearchGlial Cell Line Derived Neurotrophic Factor Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Glial Cell Line Derived Neurotrophic Factor Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Glial Cell Line Derived Neurotrophic Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glial Cell Line Derived Neurotrophic Factor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Glial Cell Line Derived Neurotrophic Factor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glial Cell Line Derived Neurotrophic Factor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Glial Cell Line Derived Neurotrophic Factor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Glial Cell Line Derived Neurotrophic Factor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Glial Cell Line Derived Neurotrophic Factor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Glial Cell Line Derived Neurotrophic Factor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Glial Cell Line Derived Neurotrophic Factor include GlaxoSmithKline Plc, UniQure NV and Treeway BV, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Glial Cell Line Derived Neurotrophic Factor, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Glial Cell Line Derived Neurotrophic Factor, also provides the revenue of main regions and countries. Of the upcoming market potential for Glial Cell Line Derived Neurotrophic Factor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glial Cell Line Derived Neurotrophic Factor revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Glial Cell Line Derived Neurotrophic Factor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Glial Cell Line Derived Neurotrophic Factor revenue, projected growth trends, production technology, application and end-user industry.

Glial Cell Line Derived Neurotrophic Factor Segment by Company

GlaxoSmithKline Plc

UniQure NV

Treeway BV

Glial Cell Line Derived Neurotrophic Factor Segment by Type

TW-002

LAUR-301

GSK-812

AMT-090

Others

Glial Cell Line Derived Neurotrophic Factor Segment by Application

Amyotrophic Lateral Sclerosis

Brain Ischemia

Parkinson's Disease

Retinal Degeneration

Others

Glial Cell Line Derived Neurotrophic Factor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glial Cell Line Derived Neurotrophic Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glial Cell Line Derived Neurotrophic Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glial Cell Line Derived Neurotrophic Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Glial Cell Line Derived Neurotrophic Factor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Glial Cell Line Derived Neurotrophic Factor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glial Cell Line Derived Neurotrophic Factor revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Glial Cell Line Derived Neurotrophic Factor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. TW-002 Major Player Table 3. LAUR-301 Major Player Table 4. GSK-812 Major Player Table 5. AMT-090 Major Player Table 6. Others Major Player Table 7. Global Glial Cell Line Derived Neurotrophic Factor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Amyotrophic Lateral Sclerosis Major Player Table 9. Brain Ischemia Major Player Table 10. Parkinson's Disease Major Player Table 11. Retinal Degeneration Major Player Table 12. Others Major Player Table 13. Glial Cell Line Derived Neurotrophic Factor Industry Trends Table 14. Glial Cell Line Derived Neurotrophic Factor Industry Drivers Table 15. Glial Cell Line Derived Neurotrophic Factor Industry Opportunities and Challenges Table 16. Glial Cell Line Derived Neurotrophic Factor Industry Restraints Table 17. Global Glial Cell Line Derived Neurotrophic Factor Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Glial Cell Line Derived Neurotrophic Factor Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Glial Cell Line Derived Neurotrophic Factor Market Share by Region (2021-2026) Table 20. Global Glial Cell Line Derived Neurotrophic Factor Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Glial Cell Line Derived Neurotrophic Factor Market Share by Region (2027-2032) Table 22. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Players (2021-2026) Table 24. Global Glial Cell Line Derived Neurotrophic Factor Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Glial Cell Line Derived Neurotrophic Factor Key Players Headquarters & Area Served Table 26. Global Glial Cell Line Derived Neurotrophic Factor Players, Product Type & Application Table 27. Global Glial Cell Line Derived Neurotrophic Factor Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Glial Cell Line Derived Neurotrophic Factor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Type (2021-2026) Table 34. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Type (2027-2032) Table 35. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Application (2021-2026) Table 39. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Application (2027-2032) Table 40. GlaxoSmithKline Plc Company Information Table 41. GlaxoSmithKline Plc Business Overview Table 42. GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Product Portfolio Table 44. GlaxoSmithKline Plc Recent Development Table 45. UniQure NV Company Information Table 46. UniQure NV Business Overview Table 47. UniQure NV Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. UniQure NV Glial Cell Line Derived Neurotrophic Factor Product Portfolio Table 49. UniQure NV Recent Development Table 50. Treeway BV Company Information Table 51. Treeway BV Business Overview Table 52. Treeway BV Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Treeway BV Glial Cell Line Derived Neurotrophic Factor Product Portfolio Table 54. Treeway BV Recent Development Table 55. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026) & (US$ Million) Table 56. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032) & (US$ Million) Table 57. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026) & (US$ Million) Table 58. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032) & (US$ Million) Table 59. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026) & (US$ Million) Table 61. North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country (US$ Million) & (2027-2032) Table 62. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026) & (US$ Million) Table 63. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032) & (US$ Million) Table 64. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026) & (US$ Million) Table 65. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032) & (US$ Million) Table 66. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026) & (US$ Million) Table 68. Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country (US$ Million) & (2027-2032) Table 69. China Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026) & (US$ Million) Table 70. China Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032) & (US$ Million) Table 71. China Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026) & (US$ Million) Table 72. China Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026) & (US$ Million) Table 74. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032) & (US$ Million) Table 75. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026) & (US$ Million) Table 76. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Region (US$ Million) & (2021-2026) Table 79. Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Region (US$ Million) & (2027-2032) Table 80. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026) & (US$ Million) Table 81. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032) & (US$ Million) Table 82. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026) & (US$ Million) Table 83. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032) & (US$ Million) Table 84. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026) & (US$ Million) Table 86. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country (US$ Million) & (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Glial Cell Line Derived Neurotrophic Factor Image Figure 2. Global Glial Cell Line Derived Neurotrophic Factor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glial Cell Line Derived Neurotrophic Factor Market Size Share 2021 VS 2025 VS 2032 Figure 4. TW-002 Image Figure 5. LAUR-301 Image Figure 6. GSK-812 Image Figure 7. AMT-090 Image Figure 8. Others Image Figure 9. Global Glial Cell Line Derived Neurotrophic Factor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Glial Cell Line Derived Neurotrophic Factor Market Size Share 2021 VS 2025 VS 2032 Figure 11. Amyotrophic Lateral Sclerosis Image Figure 12. Brain Ischemia Image Figure 13. Parkinson's Disease Image Figure 14. Retinal Degeneration Image Figure 15. Others Image Figure 16. Global Glial Cell Line Derived Neurotrophic Factor Market Size (US$ Million) & (2021-2032) Figure 17. Global Glial Cell Line Derived Neurotrophic Factor Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Glial Cell Line Derived Neurotrophic Factor Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Glial Cell Line Derived Neurotrophic Factor Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Type (2021-2032) Figure 24. Global Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Application (2021-2032) Figure 27. North America Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032) Figure 29. North America Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032) Figure 30. North America Glial Cell Line Derived Neurotrophic Factor Revenue Share by Country (2021-2032) Figure 31. United States Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032) Figure 36. Europe Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032) Figure 37. Europe Glial Cell Line Derived Neurotrophic Factor Revenue Share by Country (2021-2032) Figure 38. Germany Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032) Figure 48. China Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032) Figure 49. Asia Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032) Figure 51. Asia Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032) Figure 52. Asia Glial Cell Line Derived Neurotrophic Factor Revenue Share by Region (2021-2032) Figure 53. Japan Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032) Figure 61. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032) Figure 62. SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue Share by Country (2021-2032) Figure 63. Brazil Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Glial Cell Line Derived Neurotrophic Factor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • TW-002
  • LAUR-301
  • GSK-812
  • AMT-090
  • Others
Applications
  • Amyotrophic Lateral Sclerosis
  • Brain Ischemia
  • Parkinson's Disease
  • Retinal Degeneration
  • Others
Companies covered
  • GlaxoSmithKline Plc
  • UniQure NV
  • Treeway BV

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Glial Cell Line Derived Neurotrophic Factor Market by Type
  3. 1.2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 TW-002
  5. 1.2.3 LAUR-301
  6. 1.2.4 GSK-812
  7. 1.2.5 AMT-090
  8. 1.2.6 Others
  9. 1.3 Glial Cell Line Derived Neurotrophic Factor Market by Application
  10. 1.3.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Amyotrophic Lateral Sclerosis
  12. 1.3.3 Brain Ischemia
  13. 1.3.4 Parkinson's Disease
  14. 1.3.5 Retinal Degeneration
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Glial Cell Line Derived Neurotrophic Factor Market Dynamics
  1. 2.1 Glial Cell Line Derived Neurotrophic Factor Industry Trends
  2. 2.2 Glial Cell Line Derived Neurotrophic Factor Industry Drivers
  3. 2.3 Glial Cell Line Derived Neurotrophic Factor Industry Opportunities and Challenges
  4. 2.4 Glial Cell Line Derived Neurotrophic Factor Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Glial Cell Line Derived Neurotrophic Factor Market Perspective (2021-2032)
  2. 3.2 Global Glial Cell Line Derived Neurotrophic Factor Growth Trends by Region
  3. 3.2.1 Global Glial Cell Line Derived Neurotrophic Factor Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Glial Cell Line Derived Neurotrophic Factor Market Size by Region (2021-2026)
  5. 3.2.3 Global Glial Cell Line Derived Neurotrophic Factor Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Players
  2. 4.1.1 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Players (2021-2026)
  3. 4.1.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Glial Cell Line Derived Neurotrophic Factor Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Glial Cell Line Derived Neurotrophic Factor Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Glial Cell Line Derived Neurotrophic Factor Key Players Headquarters & Area Served
  7. 4.4 Global Glial Cell Line Derived Neurotrophic Factor Players, Product Type & Application
  8. 4.5 Global Glial Cell Line Derived Neurotrophic Factor Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Glial Cell Line Derived Neurotrophic Factor Market CR5 and HHI
  11. 4.6.3 2025 Glial Cell Line Derived Neurotrophic Factor Tier 1, Tier 2, and Tier 3
5 Glial Cell Line Derived Neurotrophic Factor Market Size by Type
  1. 5.1 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2032)
  3. 5.3 Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Type (2021-2032)
6 Glial Cell Line Derived Neurotrophic Factor Market Size by Application
  1. 6.1 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2032)
  3. 6.3 Global Glial Cell Line Derived Neurotrophic Factor Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GlaxoSmithKline Plc
  2. 7.1.1 GlaxoSmithKline Plc Company Information
  3. 7.1.2 GlaxoSmithKline Plc Business Overview
  4. 7.1.3 GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GlaxoSmithKline Plc Glial Cell Line Derived Neurotrophic Factor Product Portfolio
  6. 7.1.5 GlaxoSmithKline Plc Recent Developments
  7. 7.2 UniQure NV
  8. 7.2.1 UniQure NV Company Information
  9. 7.2.2 UniQure NV Business Overview
  10. 7.2.3 UniQure NV Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (2021-2026)
  11. 7.2.4 UniQure NV Glial Cell Line Derived Neurotrophic Factor Product Portfolio
  12. 7.2.5 UniQure NV Recent Developments
  13. 7.3 Treeway BV
  14. 7.3.1 Treeway BV Company Information
  15. 7.3.2 Treeway BV Business Overview
  16. 7.3.3 Treeway BV Glial Cell Line Derived Neurotrophic Factor Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Treeway BV Glial Cell Line Derived Neurotrophic Factor Product Portfolio
  18. 7.3.5 Treeway BV Recent Developments
8 North America
  1. 8.1 North America Glial Cell Line Derived Neurotrophic Factor Revenue (2021-2032)
  2. 8.2 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2032)
  3. 8.2.1 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026)
  4. 8.2.2 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032)
  5. 8.3 North America Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032)
  6. 8.4 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2032)
  7. 8.4.1 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026)
  8. 8.4.2 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032)
  9. 8.5 North America Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032)
  10. 8.6 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country
  11. 8.6.1 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026)
  13. 8.6.3 North America Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Glial Cell Line Derived Neurotrophic Factor Revenue (2021-2032)
  2. 9.2 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2032)
  3. 9.2.1 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026)
  4. 9.2.2 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032)
  5. 9.3 Europe Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032)
  6. 9.4 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2032)
  7. 9.4.1 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026)
  8. 9.4.2 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032)
  9. 9.5 Europe Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032)
  10. 9.6 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country
  11. 9.6.1 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026)
  13. 9.6.3 Europe Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Glial Cell Line Derived Neurotrophic Factor Revenue (2021-2032)
  2. 10.2 China Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2032)
  3. 10.2.1 China Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026)
  4. 10.2.2 China Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032)
  5. 10.3 China Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032)
  6. 10.4 China Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2032)
  7. 10.4.1 China Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026)
  8. 10.4.2 China Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032)
  9. 10.5 China Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Glial Cell Line Derived Neurotrophic Factor Revenue (2021-2032)
  2. 11.2 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2032)
  3. 11.2.1 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026)
  4. 11.2.2 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032)
  5. 11.3 Asia Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032)
  6. 11.4 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2032)
  7. 11.4.1 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026)
  8. 11.4.2 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032)
  9. 11.5 Asia Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032)
  10. 11.6 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Country
  11. 11.6.1 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026)
  13. 11.6.3 Asia Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue (2021-2032)
  2. 12.2 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Type (2027-2032)
  5. 12.3 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Application (2027-2032)
  9. 12.5 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country
  11. 12.6.1 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Glial Cell Line Derived Neurotrophic Factor Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst